Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793660 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2NOS1NOS2ALDH1A1NOS3 | |
| SCHEMBL29793575 | 0.93 | NOS1 (0.41) | SMN1; SMN2NOS1NOS2ALDH1A1NOS3 | |
| SCHEMBL4944584 | 0.84 | TAAR1 (0.38) | SMN1; SMN2NOS1TSHRLMNAGAA | |
| SCHEMBL856097 | 0.83 | OPRM1 (0.40) | SMN1; SMN2ALDH1A1ENPP2TSHRLMNA | |
| SCHEMBL6158666 | 0.83 | TSHR (0.39) | SMN1; SMN2ALDH1A1TSHRLMNAGAA | |
| SCHEMBL29866080 | 0.83 | TSHR (0.39) | SMN1; SMN2ALDH1A1TSHRLMNAGAA | |
| SCHEMBL507521 | 0.82 | HRH3 (0.39) | SMN1; SMN2NOS1NOS2NOS3LOXL2 | |
| SCHEMBL27899553 | 0.81 | TSHR (0.38) | SMN1; SMN2ALDH1A1TSHRLMNAGAA | |
| SCHEMBL27652959 | 0.80 | TSHR (0.40) | SMN1; SMN2ALDH1A1TSHRLMNAGAA | |
| SCHEMBL13571057 | 0.78 | NCF1 (0.38) | SMN1; SMN2NOS1NOS2ALDH1A1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014028931-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
| CN-101331133-A | Sulphonamidoaniline derivatives as Janus kinase inhibitors | NOVARTIS AG (CH) | 2008-12-24 | — | — | CN | disclosed |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0545376-B1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5532258-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0545376-A1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | SMN1; SMN2 4091/4885NOS1 1275/4885NOS2 633/4885 |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | SMN1; SMN2 3036/4885NOS1 864/4885NOS2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.